Insider · CIK 0001661254

Van Naarden Jacob

Reports to the SEC for 2 companies · INDIANAPOLIS, IN

sec.gov

Transactions

Companies

Filings

CIK

0001661254

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-09	LLYELI LILLY & CoA Award	EVP,Pres LLY Oncology&HdCorpBD	AAward	+4,865.888 sh	$1044.67	+$5.08M	26,626.498
2026-02-01	LLYELI LILLY & CoM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	+4,108 sh	—	—	24,669.985
2026-02-01	LLYELI LILLY & CoF Tax Payment	EVP,Pres LLY Oncology&HdCorpBD	FTax Payment	−1,909.375 sh	$1037.15	−$1.98M	22,760.61
2026-02-01	LLYELI LILLY & Co · Restricted Stock UnitM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	−4,108 sh	—	—	0
2025-08-13	LLYELI LILLY & CoP Purchase	EVP,Pres LLY Oncology&HdCorpBD	PPurchase	+1,000 sh	$647.36	+$647K	20,561.985
2025-02-10	LLYELI LILLY & CoA Award	EVP,Pres LLY Oncology&HdCorpBD	AAward	+6,103.824 sh	$868.88	+$5.3M	19,561.985
2025-02-10	LLYELI LILLY & Co · Restricted Stock UnitA Award	EVP,Pres LLY Oncology&HdCorpBD	AAward	+4,108 sh	—	—	4,108
2025-02-01	LLYELI LILLY & CoM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	+3,023 sh	—	—	14,868
2025-02-01	LLYELI LILLY & CoF Tax Payment	EVP,Pres LLY Oncology&HdCorpBD	FTax Payment	−1,409.839 sh	$811.08	−$1.14M	13,458.161
2025-02-01	LLYELI LILLY & Co · Restricted Stock UnitM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	−3,023 sh	—	—	0
2024-10-31	LLYELI LILLY & CoG Gift	EVP,Pres LLY Oncology&HdCorpBD	GGift	−4,302 sh	—	—	11,845
2024-02-12	LLYELI LILLY & CoA Award	EVP,Pres LLY Oncology&HdCorpBD	AAward	+2,369 sh	$737.26	+$1.75M	16,147
2024-02-12	LLYELI LILLY & Co · Restricted Stock UnitA Award	EVP,Pres LLY Oncology&HdCorpBD	AAward	+3,023 sh	—	—	3,023
2024-02-01	LLYELI LILLY & CoM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	+3,618 sh	—	—	15,463
2024-02-01	LLYELI LILLY & CoF Tax Payment	EVP,Pres LLY Oncology&HdCorpBD	FTax Payment	−1,685 sh	$645.61	−$1.09M	13,778
2024-02-01	LLYELI LILLY & Co · Restricted Stock UnitM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	−3,618 sh	—	—	0
2023-02-16	LLYELI LILLY & CoM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	+2,785 sh	—	—	13,159
2023-02-16	LLYELI LILLY & CoF Tax Payment	EVP,Pres LLY Oncology&HdCorpBD	FTax Payment	−1,314 sh	$335.01	−$440K	11,845
2023-02-16	LLYELI LILLY & Co · Restricted Stock UnitM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	−2,785 sh	—	—	0
2023-02-10	LLYELI LILLY & CoA Award	EVP,Pres LLY Oncology&HdCorpBD	AAward	+2,407 sh	$345.12	+$831K	10,374
2022-02-16	LLYELI LILLY & CoM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	+5,461 sh	—	—	10,153
2022-02-16	LLYELI LILLY & CoF Tax Payment	EVP,Pres LLY Oncology&HdCorpBD	FTax Payment	−2,186 sh	$243.84	−$533K	7,967
2022-02-16	LLYELI LILLY & Co · Restricted Stock UnitM Exercise/Conversion	EVP,Pres LLY Oncology&HdCorpBD	MExercise/Conversion	−5,461 sh	—	—	0
2021-12-28	LLYELI LILLY & Co · Restricted Stock UnitA Award	EVP,Pres LLY Oncology&HdCorpBD	AAward	+3,618 sh	—	—	3,618
2019-02-15	Loxo Oncology, Inc.D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−19K sh	$235.00	−$4.47M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−35K sh	$235.00	−$8.23M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−78.9K sh	$235.00	−$18.6M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−43K sh	$235.00	−$10.1M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−74K sh	$235.00	−$17.4M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−35K sh	$235.00	−$8.23M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−200K sh	$235.00	−$47M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Operating Officer	DDisposition to Issuer	−57K sh	$235.00	−$13.4M	0
2019-01-02	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+57K sh	—	—	57,000
2018-12-11	Loxo Oncology, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,500 sh	$13.67	+$61.5K	18,200
2018-12-11	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−400 sh	$134.74	−$53.9K	17,800
2018-12-11	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−800 sh	$135.92	−$109K	17,000
2018-12-11	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−1,759 sh	$137.09	−$241K	15,241
2018-12-11	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−500 sh	$137.73	−$68.9K	14,741
2018-12-11	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−500 sh	$139.23	−$69.6K	14,241
2018-12-11	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−541 sh	$140.16	−$75.8K	13,700
2018-12-11	Loxo Oncology, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+7,000 sh	$3.65	+$25.5K	20,700
2018-12-11	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,500 sh	—	—	78,943
2018-12-11	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−7,000 sh	—	—	33,326
2018-12-10	Loxo Oncology, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,500 sh	$13.67	+$61.5K	18,200
2018-12-10	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−400 sh	$130.59	−$52.2K	17,800
2018-12-10	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−1,000 sh	$132.23	−$132K	16,800
2018-12-10	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−900 sh	$133.17	−$120K	15,900
2018-12-10	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−1,400 sh	$134.65	−$189K	14,500
2018-12-10	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−500 sh	$135.14	−$67.6K	14,000
2018-12-10	Loxo Oncology, Inc.S Sale	Chief Operating Officer	SSale	−200 sh	$136.48	−$27.3K	13,800

Recent filings

Accepted (ET)
Feb 114
Van Naarden Jacob0001661254-26-000004
SEC(opens sec.gov)
Feb 34
Van Naarden Jacob0001661254-26-000002
SEC(opens sec.gov)
Aug 134
Van Naarden Jacob0000059478-25-000218
SEC(opens sec.gov)
Feb 124
Van Naarden Jacob0000059478-25-000057
SEC(opens sec.gov)
Feb 44
Van Naarden Jacob0000059478-25-000030
SEC(opens sec.gov)
Nov 14
Van Naarden Jacob0000059478-24-000247
SEC(opens sec.gov)
Feb 144
Van Naarden Jacob0000059478-24-000058
SEC(opens sec.gov)
Feb 24
Van Naarden Jacob0000059478-24-000015
SEC(opens sec.gov)
Feb 214
Van Naarden Jacob0000059478-23-000079
SEC(opens sec.gov)
Feb 144
Van Naarden Jacob0000059478-23-000065
SEC(opens sec.gov)

Companies

Address

LILLY CORPORATE CENTER

INDIANAPOLIS, IN, 46285